-
FDA approves Retrophin's Thiola EC (sulfur pronen) 100mg and 300mg tablets
Time of Update: 2020-06-09
, http:// the u.S Food and Drug (http:// Administration (http:// and the u.S http:// has approved Thiola EC 100mg and 300mg tablets, the company announced Thiola EC is a new intestinal solut
-
CHMP recommends approval of Alexion's ultomiris (ravulizumab) for the treatment of haemoglobinuria
Time of Update: 2020-06-09
recently, Alexion (http:// announced that the European medicines (http:// Authority ( HTTP://WWW.CHEMDRUG.COM/) Product http:// sons and http:// (http:// Committee (CHMP) has issued an act
-
FDA approves Pfizer Ruxience for adult patients to treat a wide range of diseases
Time of Update: 2020-06-09
recently, Pfizer announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has approved Ruxience (rituximab-pvvr, ritusxixipro, rituxixixim) for the treatment of adult patie
-
FDA approves Vraylar (Cariprazine) extended indications jointly developed by ElJian and Gedeon Richter
Time of Update: 2020-06-09
today, Allergan and Gedeon Richter announced The FDA (http:// approved its co-development of Vraylar (Cariprazine, Calipraquin) extended indications to treat depressive episodes associated with t
-
Tamabian Mitsubishi submits Application for New Drug for Vadadustat to Japan's Ministry of Health, Labour and Welfare
Time of Update: 2020-06-09
Recently, Akebia Therapeutics announced that its partner, Mitsubishi Tanaka, has submitted Vadadustat's New Drug (http:// Listing Application (JNDA) to Japan's Ministry of Health, Labour and Welf
-
Health Canada approves new kiPomalyste with Velcade and dexamethasone for treatment of adult patients with myeloma
Time of Update: 2020-06-09
recently announced that Health Canada has approved Pomalyste (pomalidomide, Pomadomide) and Velcade (bortezomib, bortezomib) and dexamethasone three-drug program (PVd) for adults who have previously
-
Seattle submits application to FDA for listing of antibody-linked drug enfortumab vedotin
Time of Update: 2020-06-09
recently, Seattle Genetics/Astellas jointly announced to the FDA (http:// to submit a market application (BLA) for the enfortumab vedotin in the research antibody association drug (http:// for
-
FDA approves Ppelisib to work with Fulvestrant to treat breast cancer patients
Time of Update: 2020-06-09
recently, the United States The FDA (http:// approve disapprove of the Piqray pill, in conjunction with the Endocrine Therapy Drug (http:// Fulvestrant, to treat patients with premenopausal wo
-
FDA accepts new drug application from Melinta's Baxdela
Time of Update: 2020-06-09
CABP is pneumonia that is infected outside the Medical (http:// facility The most common pathogens are streptococcus pneumoniae, haemophilus influenzae type flue goecole and atypical bacteria (e.
-
FDA approves Botulinum Toxin A, BOTOX to expand indications
Time of Update: 2020-06-09
recently, Allergan announced that it The FDA (http:// approved its Botulinum Toxin A,BOTOX expansion algelisted indications to treat upper limb spasms in children (2 to 17 years old) in addition
-
FDA grants Keytruda and Lenvima combination therapy to treat patients with advanced, non-reprectoable hepatocellular carcinoma
Time of Update: 2020-06-09
today, MSD and Eisai jointly announced that the u.S FDA (http:// has awarded Keytruda and Lenvima breakthrough therapies for advanced, non-reprecentable patients with advanced, non-reprecision in
-
FDA approves BAVENCIO in association with axiathani as a first-line treatment for patients with advanced renal cell carcinoma (RCC)
Time of Update: 2020-06-09
recently, the United States The FDA (http:// approved BAVENCIO (Avelumab) in conjunction with INLYTA as a first-line treatment for patients with advanced renal cell carcinoma (RCC) this is also
-
FDA approves Roche/Abbvie's Venclexta and Gazyva to combine treatments for CLL or SLL
Time of Update: 2020-06-09
recently, the United States The FDA (http:// approved Roche/AbbVie's Venclexta and Gazyva as a first-line therapy for first-stage treatment of patients with chronic lymphocytic leukemia (CLL) or
-
Xi'an Yangsen IL-12 and IL-23 inhibitors Starno ® (Usnu mono-anti-injection) are available in China
Time of Update: 2020-06-09
Recently, johnson and company (http:// in China Pharmaceutical (http:// subsidiary Xi'an Yangsen Pharmaceutical Co., Ltd announced that its all-human source "double-target" leukocyte interleuk
-
MHLW approves first three-year oral FLT3 inhibitor Vanflytinib to be launched
Time of Update: 2020-06-09
AML is a rapidly developing blood and bone marrow cancer, and cancerous white blood cells in patients are growing rapidly, not only do they fail to function normally, but also affect the production
-
Bayer announces FDA-approved breakthrough treatment for anti-cancer drug Aliqopa
Time of Update: 2020-06-09
Today, bayer (http:// announced that its anti-cancer drug (http:// Aliqolisib has been identified by the FDA (http:// as a breakthrough therapy for patients with recurrent marginal icilloma
-
EU grants Libtayo ® (cemiplimab) listing license for treatment of CSCC adult patients
Time of Update: 2020-06-09
recently, Sanofi and Regeneration announced that the European Union has granted Libtayo ® a conditional listing license for the treatment of adult patients with metastatic or localized advanced skin
-
Fosun Pharma receives approval of supplementary drug application slots issued by the State Drug Administration
Time of Update: 2020-06-09
recently, Shanghai Fosun Pharmaceutical (http:// (Group) limited shares company (http:// (hereinafter referred to as "Fosun Pharma"), its controlling subsidiary Shenyang Red Flag Pharmaceutic
-
Novo Nordisk releases data on ElLipsE, Phase III clinical study of Victoza (liraglutide, liraglutide)
Time of Update: 2020-06-09
recently, diabetes giant Novo Nordisk released data from elLipsE, a phase III clinical study of Victoza The study, the first Phase III study to be completed in the past 10 years in a group of chil
-
Yimin Angko Next Generation Immune Checkpoint Inhibitors Approved for Treatment of Blood Cancers in NMPA Clinical Trials
Time of Update: 2020-06-09
recently, , Yimin Angko Bio Pharmaceutical (http:// Technology (Shanghai) Limited Company (http:// ("Yimin Angko"), announced that the company's new generation of immunocheckpoint inhibitors (it
